Dr. Arun Iyer and Dr. Samaresh Sau, Wayne State University.
Dr. Arun Iyer and Dr. Samaresh Sau, Wayne State University.

Credit: Julie O'Connor, Wayne State University

News • Cancer

Drug-resistant renal cell carcinoma: Nanotherapy offers hope

A research team led by Arun Iyer, Ph.D., assistant professor of pharmaceutical sciences in the Eugene Applebaum College of Pharmacy and Health Sciences at Wayne State University, has developed a nanoplatform technology that works in combination with existing chemotherapeutic drugs that may reverse drug-resistance in renal cell carcinoma.

Drug resistance to chemotherapy is a significant clinical and financial burden in renal cell carcinoma and other types of cancers. The resistance can be caused by hypoxia, a decreased level of oxygen in the tumor cells and infiltration of tumor-promoting immune cells aiding the tumor growth in contrast to fighting against it.

To alleviate the drug resistance, Iyer, principal investigator on the project, and co-investigator and lead author of the work, Samaresh Sau, Ph.D., research associate in the Department of Pharmaceutical Sciences in the Eugene Applebaum College of Pharmacy and Health Sciences, set out to find a way to use tumor hypoxia-directed nanoparticles to attack the root cause of the problem

“Our tumor hypoxia directed nanoparticle used in conjunction with the FDA-approved renal cell carcinoma treatment, Sorafenib, has had positive outcomes in our animal trials,” said Iyer. “The nanoparticles can deliver the payload selectively to tumor tissue and penetrate deep into the tumor core and provoke significant tumor inhibition with marked safety.”

According to the duo, the results have shown that this targeted approach has great benefits. “This hypoxia targeting nanoparticles is not only effective in inhibiting tumor-promoting immune cells but also enhancing function of tumor-killing immune cells,” said Sau. “Another important aspect of the nanoparticle is that it can precisely diagnose renal tumors non-invasively that can be utilized for tumor detection, staging and surgery in the clinical setting.”

Iyer and Sau stated that along with reversing drug-resistance and helping the immune system work properly, their technology will also save money by repurposing existing drugs to function better with reduced side effects of chemotherapy treatment because of its targeted approach. It also has potential to treat other cancers that have been difficult to treat or have become drug-resistant to current therapies.

“This new approach of using our nanoplatform will reopen doors that were once closed because drugs that had become ineffective to cancer treatment are now once again usable and effective,” said Iyer. “It is our hope that this research will one day soon be used in clinics for treating patients.”

Source: Wayne State University Division of Research

01.10.2018

Read all latest stories

Related articles

Photo

News • New study

Can physical exercise enhance the effect of chemotherapy against breast cancer?

Many women diagnosed with breast cancer can be cured with surgery, radiotherapy and medical treatment. Swedish researchers explore whether physical exercise can support the anti-tumour effects.

Photo

News • NSCLC

Liquid biopsy as effective as tissue biopsy for non-small cell lung cancer

Test more accurately identifies four mutations for which FDA-approved drugs exist and offers faster turn-around time between initial testing and commencement of therapy.

Photo

News • Reinforced learning

AI masters tightrope walk of cancer treatment dosage

Using a new approach called 'reinforced learning', researchers have taught an artificial intelligence (AI) to responsibly choose the right amount of chemo- and radiotherapy for glioblastoma patients.…

Related products

Canon – Alphenix 4D CT

Multi-Modality Suites

Canon – Alphenix 4D CT

Canon Medical Systems Europe B.V.
Canon - Aquilion Exceed LB

Oncology CT

Canon - Aquilion Exceed LB

Canon Medical Systems Europe B.V.
Canon – Aquilion LB

Oncology CT

Canon – Aquilion LB

Canon Medical Systems Europe B.V.
Canon – Vitrea Advanced Visualization

Reading

Canon – Vitrea Advanced Visualization

Canon Medical Systems Europe B.V.
Siemens Healthineers – Somatom Edge Plus

Oncology CT

Siemens Healthineers – Somatom Edge Plus

Siemens Healthineers
Subscribe to Newsletter